Last reviewed · How we verify

Haemophilus Parainfluenzae Pneumonia — Treatment Landscape & Competitive Intelligence

Haemophilus Parainfluenzae Pneumonia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Haemophilus Parainfluenzae Pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zymar GATIFLOXACIN Allergan DNA gyrase, DNA gyrase, DNA gyrase subunit A 2003-01-01
Cefditoren Pivoxyl CEFDITOREN PIVOXIL Vansen Pharma Cephalosporin Antibacterial 2001-01-01
Levaquin levofloxacin Generic (originally Daiichi Sankyo/J&J) Fluoroquinolone Antibacterial [EPC] CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2 1996-12-20
Biaxin clarithromycin Generic (originally Abbott/AbbVie) Macrolide Antimicrobial [EPC] Potassium voltage-gated channel subfamily H member 2 1991-10-31
Cipro ciprofloxacin Bayer AG Fluoroquinolone antibiotic DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A 1987-10-22
Rocephin ceftriaxone Generic (originally Roche) Cephalosporin antibiotic (third-generation) Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A 1984-12-21
Augmentin 250 CLAVULANIC ACID Dr Reddys Labs Inc beta Lactamase Inhibitor 1984-01-01
Claforan CEFOTAXIME Sterimax Cephalosporin Antibacterial 1981-01-01
Amoxil amoxicillin Generic (originally Beecham/GSK) Aminopenicillin (Beta-lactam antibiotic) 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C 1972-01-01
Amoxicilli Amoxicilli Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 5 drugs in Haemophilus Parainfluenzae Pneumonia
  2. Allergan · 1 drug in Haemophilus Parainfluenzae Pneumonia
  3. Assistance Publique - Hôpitaux de Paris · 1 drug in Haemophilus Parainfluenzae Pneumonia
  4. Bayer AG · 1 drug in Haemophilus Parainfluenzae Pneumonia
  5. Centre Hospitalier Universitaire Vaudois · 1 drug in Haemophilus Parainfluenzae Pneumonia
  6. Dr Reddys Labs Inc · 1 drug in Haemophilus Parainfluenzae Pneumonia
  7. Generic (originally Abbott/AbbVie) · 1 drug in Haemophilus Parainfluenzae Pneumonia
  8. Generic (originally Beecham/GSK) · 1 drug in Haemophilus Parainfluenzae Pneumonia
  9. Generic (originally Daiichi Sankyo/J&J) · 1 drug in Haemophilus Parainfluenzae Pneumonia
  10. Generic (originally Roche) · 1 drug in Haemophilus Parainfluenzae Pneumonia
  11. King George's Medical University · 1 drug in Haemophilus Parainfluenzae Pneumonia
  12. Poitiers University Hospital · 1 drug in Haemophilus Parainfluenzae Pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Haemophilus Parainfluenzae Pneumonia:

Cite this brief

Drug Landscape (2026). Haemophilus Parainfluenzae Pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/haemophilus-parainfluenzae-pneumonia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing